

# Scott E Hensley

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3798054/scott-e-hensley-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104  
papers

6,407  
citations

40  
h-index

79  
g-index

114  
ext. papers

9,503  
ext. citations

15  
avg, IF

5.93  
L-index

#	Paper	IF	Citations
104	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <i>Science</i> , <b>2020</b> , 369,	33.3	744
103	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. <i>Nature</i> , <b>2017</b> , 543, 248-251	50.4	502
102	Comprehensive mapping of immune perturbations associated with severe COVID-19. <i>Science Immunology</i> , <b>2020</b> , 5,	28	387
101	Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. <i>Science</i> , <b>2009</b> , 326, 734-6	33.3	364
100	Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 12578-12583	11.5	312
99	Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. <i>Science Immunology</i> , <b>2021</b> , 6,	28	237
98	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 1571-1588	16.6	212
97	Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 15798-803	11.5	159
96	Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. <i>Cell</i> , <b>2021</b> , 184, 1858-1864.e10	56.2	155
95	Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015 Influenza Season. <i>Cell Reports</i> , <b>2015</b> , 12, 1-6	10.6	143
94	A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006682	7.6	143
93	Immune history and influenza virus susceptibility. <i>Current Opinion in Virology</i> , <b>2017</b> , 22, 105-111	7.5	139
92	Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. <i>Nature Medicine</i> , <b>2021</b> , 27, 1990-2001	50.5	138
91	mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. <i>Science</i> , <b>2021</b> , 374, abm0829	33.3	133
90	Immune history shapes specificity of pandemic H1N1 influenza antibody responses. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 1493-500	16.6	130
89	Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. <i>Nature Communications</i> , <b>2018</b> , 9, 3361	17.4	120
88	Rapid induction of antigen-specific CD4 T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. <i>Immunity</i> , <b>2021</b> , 54, 2133-2142.e3	32.3	117

87	Cutting Edge: IL-4, IL-21, and IFN- $\gamma$ Interact To Govern T-bet and CD11c Expression in TLR-Activated B Cells. <i>Journal of Immunology</i> , <b>2016</b> , 197, 1023-8	5.3	108
86	CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , <b>2021</b> , 27, 1280-1289	50.5	103
85	Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, E1417-22	11.5	102
84	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 195-202	11.5	102
83	Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios. <i>JAMA Pediatrics</i> , <b>2021</b> , 175, 594-600	8.3	96
82	Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells. <i>Science Immunology</i> , <b>2017</b> , 2,	28	94
81	SARS-CoV-2 seroprevalence among parturient women in Philadelphia. <i>Science Immunology</i> , <b>2020</b> , 5,	28	84
80	Complete mapping of viral escape from neutralizing antibodies. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006271	7.6	80
79	Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. <i>Cell Host and Microbe</i> , <b>2019</b> , 25, 357-366.e6	23.4	79
78	Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. <i>Science Immunology</i> , <b>2021</b> , 6,	28	74
77	The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans. <i>Immunity</i> , <b>2020</b> , 52, 842-855.e6	32.3	64
76	Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. <i>Journal of Immunology</i> , <b>2005</b> , 175, 6032-41	5.3	63
75	Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. <i>Molecular Therapy</i> , <b>2007</b> , 15, 393-403	11.7	61
74	Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. <i>Blood Advances</i> , <b>2020</b> , 4, 6051-6063	7.8	57
73	Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. <i>PLoS ONE</i> , <b>2011</b> , 6, e15190	3.7	57
72	Single hemagglutinin mutations that alter both antigenicity and receptor binding avidity influence influenza virus antigenic clustering. <i>Journal of Virology</i> , <b>2013</b> , 87, 9904-10	6.6	55
71	Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. <i>Current Opinion in Virology</i> , <b>2014</b> , 8, 85-9	7.5	53
70	Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions <b>2020</b> ,		52

69	Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin. <i>ELife</i> , <b>2019</b> , 8,	8.9	47
68	Human Influenza A Virus Hemagglutinin Glycan Evolution Follows a Temporal Pattern to a Glycan Limit. <i>MBio</i> , <b>2019</b> , 10,	7.8	45
67	Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1947-1951	7	45
66	Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, S38-S45	7	41
65	Antibodies with Original Antigenic Sin Properties Are Valuable Components of Secondary Immune Responses to Influenza Viruses. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005806	7.6	40
64	Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 327-333	11.6	36
63	Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses. <i>Journal of Virology</i> , <b>2014</b> , 88, 10986-9	6.6	34
62	Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 17221-17227	11.5	29
61	Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). <i>Journal of the Pediatric Infectious Diseases Society</i> , <b>2021</b> , 10, 669-673	4.8	29
60	Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28693	3	28
59	Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection <b>2020</b> ,		27
58	Propagation and Characterization of Influenza Virus Stocks That Lack High Levels of Defective Viral Genomes and Hemagglutinin Mutations. <i>Frontiers in Microbiology</i> , <b>2016</b> , 7, 326	5.7	27
57	Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	23
56	Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy		23
55	mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern <b>2021</b> ,		23
54	Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. <i>Nature Communications</i> , <b>2020</b> , 11, 4566	17.4	22
53	Compensatory hemagglutinin mutations alter antigenic properties of influenza viruses. <i>Journal of Virology</i> , <b>2013</b> , 87, 11168-72	6.6	18
52	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals.. <i>Cell</i> , <b>2022</b> ,	56.2	17

51	Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection <b>2020</b> ,		17
50	Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination <b>2021</b> ,		17
49	Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1447-1453	11.6	16
48	Sera from Individuals with Narrowly Focused Influenza Virus Antibodies Rapidly Select Viral Escape Mutations. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	15
47	Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination		15
46	Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies. <i>Virology</i> , <b>2017</b> , 508, 1-6	3.6	14
45	Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain. <i>Vaccine</i> , <b>2018</b> , 36, 4095-4101	4.1	13
44	Challenges of Making Effective Influenza Vaccines. <i>Annual Review of Virology</i> , <b>2020</b> , 7, 495-512	14.6	12
43	Deep Immune Profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19 <b>2020</b> ,		12
42	Signaling through FcRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19 <b>2021</b> ,		12
41	A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. <i>Journal of Clinical Investigation</i> , <b>2021</b> ,	15.9	11
40	Influenza Vaccines Delivered in Early Childhood Could Turn Antigenic Sin into Antigenic Blessings. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2020</b> , 10,	5.4	11
39	CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer <b>2021</b> ,		11
38	Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine.. <i>Cell</i> , <b>2022</b> ,	56.2	11
37	Antigenic assessment of the H3N2 component of the 2019-2020 Northern Hemisphere influenza vaccine. <i>Nature Communications</i> , <b>2020</b> , 11, 2445	17.4	10
36	Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	10
35	Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans. <i>Cell Reports</i> , <b>2019</b> , 29, 4460-4470.e8	10.6	10
34	Genomic Circuitry Underlying Immunological Response to Pediatric Acute Respiratory Infection. <i>Cell Reports</i> , <b>2018</b> , 22, 411-426	10.6	9

33	Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	9
32	Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization.. <i>Journal of Infectious Diseases</i> , <b>2022</b> ,	7	8
31	Landscape of coordinated immune responses to H1N1 challenge in humans. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5800-5816	15.9	8
30	SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19 <b>2020</b> ,		8
29	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals <b>2021</b> ,		8
28	Author response: Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin <b>2019</b> ,		7
27	Pre-existing heterosubtypic immunity provides a barrier to airborne transmission of influenza viruses. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009273	7.6	7
26	SARS-CoV-2 Seroprevalence Among Parturient Women		5
25	Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin		5
24	SARS-CoV-2 Seroprevalence Among Parturient Women <b>2020</b> ,		4
23	Antigenic and virological properties of an H3N2 variant that continues to dominate the 2021-22 Northern Hemisphere influenza season. <i>Cell Reports</i> , <b>2022</b> , 39, 110897	10.6	4
22	SARS-CoV-2 spike protein binding selectively accelerates substrate-specific catalytic activity of ACE2. <i>Journal of Biochemistry</i> , <b>2021</b> , 170, 299-306	3.1	3
21	Sero-monitoring of health care workers reveals complex relationships between common coronavirus antibodies and SARS-CoV-2 severity <b>2021</b> ,		3
20	An Egg-Derived Sulfated -Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. <i>MBio</i> , <b>2021</b> , 12, e0083821	7.8	3
19	The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4 T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway. <i>Vaccine</i> , <b>2018</b> , 36, 3650-3665	4.1	3
18	Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility		2
17	Pre-existing immunity provides a barrier to airborne transmission of influenza viruses		2
16	Despite egg-adaptive mutations, the 2012-13 H3N2 influenza vaccine induced comparable antibody titers to the intended strain		2

15	Vaccination reshapes the virus-specific T cell repertoire in unexposed adults. <i>Immunity</i> , <b>2021</b> , 54, 1245-1256.e52		
14	Transplacental Transfer of SARS-CoV-2 Antibodies		1
13	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations		1
12	Sera from individuals with narrowly focused influenza virus antibodies rapidly select viral escape mutations in ovo		1
11	Assessing the protective potential of H1N1 influenza virus hemagglutinin head and stalk antibodies in humans		1
10	An egg-derived sulfated N-Acetylglucosamine glycan is an antigenic decoy of influenza virus vaccines		1
9	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e1879-e1886	2.3	1
8	Canine H3N8 influenza vaccines partially protect mice against the canine H3N2 strain currently circulating in the United States. <i>Vaccine</i> , <b>2016</b> , 34, 5483-5487	4.1	1
7	Potential Antigenic Mismatch of the H3N2 Component of the 2019 Southern Hemisphere Influenza Vaccine. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 2432-2434	11.6	1
6	SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy <b>2021</b> ,		1
5	Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. <b>2022</b> ,		1
4	Signaling Through FcRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 834988	8.4	1
3	Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 1-24	2	0
2	Neighborhood Characteristics and Racial Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seropositivity in Pregnancy. <i>Obstetrics and Gynecology</i> , <b>2022</b> , 139, 1018-1024	4.9	0
1	The 2009 Pandemic H1N1 Hemagglutinin Stalk Remained Antigenically Stable after Circulating in Humans for a Decade.. <i>Journal of Virology</i> , <b>2022</b> , e0220021	6.6	